Abstract
Background Excessive daytime sleepiness (EDS) is one of the most common non-motor symptoms in Parkinson’s disease (PD). Previous studies showed that PD patients with EDS exhibited more severe motor and non-motor symptoms. Our recent studies revealed that BIN3 rs2280104 was negatively associated with scores of Epworth Sleepiness Scale (ESS) in PD patients. The objective of this study is to examine whether BIN3 rs2280104 shapes brain networks of PD patients and whether network metrics associated with BIN3 rs2280104 mediate the effects of BIN3 rs2280104 on EDS.
Methods PD patients (n = 144) receiving functional magnetic resonance imaging in Parkinson’s Progression Markers Initiative (PPMI) database were investigated. The clinical manifestations and graphical metrics of structural and functional network were compared among different genotype groups of BIN3 rs2280104. The mediation analysis was used to explore the causal associations between network metrics modified by BIN3 rs2280104 and EDS of PD patients.
Results ESS scores were associated with more severe motor and non-motor symptoms. BIN3 rs2280104 T allele was negatively associated with ESS scores in PD patients. Additionally, BIN3 rs2280104 significantly shaped structural and functional network metrics of PD patients. The nodal Cp of left superior temporal pole in functional network and the degree centrality of left calcarine in structural network were negatively associated with ESS scores, however, only the degree centrality of left calcarine in structural network mediated the effects of BIN3 rs2280104 on EDS of PD patients.
Conclusions To summarize, BIN3 rs2280104 is significantly associated with EDS and network topology of PD patients. Additionally, the degree centrality of left calcarine in structural network mediated the effects of BIN3 rs2280104 on EDS. Future studies were required to identify the molecular mechanisms underlying the effects of BIN3 rs2280104 on EDS and brain network metrics of PD patients.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was supported by grants from National Natural Science Foundation of China (Grant No. 81873778, 82071415) and National Research Center for Translational Medicine at Shanghai, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine (Grant No. NRCTM(SH)-2021-03).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data availability
All the raw data used in the preparation of this Article were downloaded from PPMI database (www.ppmi-info.org/data). All data produced in the present study are available upon reasonable request to the authors.
